Ceftaroline + Ceftriaxone
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Community-Acquired Bacterial Pneumonia
Conditions
Community-Acquired Bacterial Pneumonia, Lung Infection of Individual Not Recently Hospitalized
Trial Timeline
Dec 1, 2011 → May 1, 2013
NCT ID
NCT01371838About Ceftaroline + Ceftriaxone
Ceftaroline + Ceftriaxone is a phase 3 stage product being developed by Pfizer for Community-Acquired Bacterial Pneumonia. The current trial status is completed. This product is registered under clinical trial identifier NCT01371838. Target conditions include Community-Acquired Bacterial Pneumonia, Lung Infection of Individual Not Recently Hospitalized.
What happened to similar drugs?
1 of 7 similar drugs in Community-Acquired Bacterial Pneumonia were approved
Approved (1) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01371838 | Phase 3 | Completed |
Competing Products
9 competing products in Community-Acquired Bacterial Pneumonia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ONO-5046Na + ONO-5046Na | Ono Pharmaceutical | Phase 2 | 35 |
| Azithromycin microspheres 2.0 single dose | Pfizer | Phase 3 | 40 |
| IV azithromycin + ceftriaxone + oral azithromycin + IV levofloxacin + oral levofloxacin | Pfizer | Approved | 43 |
| Azithromycin SR | Pfizer | Phase 3 | 40 |
| Azithromycin SR + Amoxiclav | Pfizer | Pre-clinical | 18 |
| tigecycline | Pfizer | Phase 3 | 40 |
| Tigecycline + Levofloxacin | Pfizer | Phase 3 | 40 |
| Omadacycline + Moxifloxacin | Zai Lab | Phase 3 | 41 |
| ceftobiprole medocaril + IV standard-of-care cephalosporin | Basilea Pharmaceutica | Phase 3 | 34 |